prt7732
·Code: PRT7732
prt7732: 1 clinical trial tracked.
prt7732 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about prt7732, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4
Primary endpoint: Dose Limiting toxicity (DLT) of PRT7732
Interventionalopen42 targetStarted 2024-11Completion 2026-0128 sites · Australia, Germany, Japan, South Korea…Prelude Therapeutics